Gilead to Present Latest Scientific Research in Hematologic Malignancies and Solid Tumors at ASH 2018

Gilead to Present Latest Scientific Research in Hematologic Malignancies and Solid Tumors at ASH 2018

FOSTER CITY, Calif.–(BUSINESS WIRE)–Nov. 1, 2018– Gilead Sciences, Inc. (Nasdaq: GILD) today announced data from its oncology and cell therapy research programs will be presented at the 60th American Society of Hematology (ASH) Annual Meeting & Exposition, in San Diego from December 1 – 4, 2018. Twelve abstracts will be presented, including data highlighting Gilead’s broad cell therapy pipeline in hematologic malignancies and solid tumors.

Notable data to be presented at the meeting include new analyses from the ZUMA chimeric antigen receptor T (CAR T) cell therapy development program, including long-term data from the Yescarta® (axicabtagene ciloleucel) ZUMA-1 trial showing efficacy and safety results with a minimum follow-up of two years in certain patients with refractory large B-cell lymphoma, and updates to the ZUMA-3 study evaluating investigational KTE-X19 (formerly KTE-C19) in adult patients with relapsed or refractory acute lymphoblastic leukemia (ALL). Data from two trials as part of Cooperative Research and Development Agreements (CRADAs) between the Experimental Transplantation and Immunology Branch (ETIB) of the National Cancer Institute (NCI) Center for Cancer Research and Kite, a Gilead Company, to further the research and clinical development of cell therapies, including a T cell receptor (TCR) product candidate for the treatment of HPV-associated solid tumors, will also be presented in oral sessions.

“At Gilead and Kite, we are proud to be leading the field of cell therapy with our research and development efforts on behalf of patients,” said Alessandro Riva, MD, Gilead’s Executive Vice President, Oncology Therapeutics & Head, Cell Therapy. “We look forward to sharing data at ASH that highlight the long-term treatment observed with Yescarta in refractory large B-cell lymphoma, as well as the potential of our pipeline of investigational cell therapies in treating other advanced cancers.”

Yescarta was the first CAR T cell therapy to be approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma and DLBCL arising from follicular lymphoma. Yescarta is not indicated for the treatment of patients with primary central nervous system lymphoma.

https://www.gilead.com/

November 6, 2018 / Pharma News